Richard J. O. Barnard

发表

Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence

A. Perelson, Tanmoy Bhattacharya, G. Shaw, 2018, Proceedings of the National Academy of Sciences.

Association between First-Year Virological Response to Raltegravir and Long-Term Outcomes in Treatment-Experienced Patients with HIV-1 Infection

B. Clotet, D. Cooper, R. Steigbigel, 2015, Antiviral therapy.

Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir.

James I. Fells, D. Klein, R. Myers, 2020, Bioorganic & medicinal chemistry letters.

Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells

B. Clotet, J. Martinez-Picado, J. Prado, 2019, Front. Immunol..

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

B. Clotet, C. Katlama, J. Gatell, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4+ T Cells

D. Hazuda, R. Sékaly, S. Deeks, 2019, Journal of Virology.

Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction

P. Coleman, Christopher D. Cox, D. Klein, 2021, ACS medicinal chemistry letters.

Discovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen.

Peter S. Kutchukian, A. W. Shaw, Jing Li, 2020, ACS medicinal chemistry letters.

Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.

E. Gane, E. Lawitz, L. Serfaty, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naïve patients with chronic hepatitis C: A randomized phase II study

M. Manns, P. Marcellin, C. Yeh, 2012, Hepatology.

Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapy

D. Hazuda, R. Sékaly, N. Shenvi, 2022, The Journal of clinical investigation.

Differentiation to an effector memory phenotype potentiates HIV-l latency reversal in CD4+ T cells

D. Hazuda, R. Sékaly, S. Deeks, 2019 .

A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.

E. Gane, E. Lawitz, L. Serfaty, 2013, Journal of hepatology.

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

B. Clotet, J. Gatell, D. Cooper, 2013, The Lancet. Infectious diseases.

HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

D. Hazuda, M. Swanson, D. Graham, 2017, JCI insight.

Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group.

D. Klein, M. Holloway, B. Howell, 2020, ACS medicinal chemistry letters.

Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.

James I. Fells, D. Klein, R. Myers, 2020, Bioorganic & medicinal chemistry letters.

Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance.

James I. Fells, Joseph James Duffy, D. Klein, 2020, ACS medicinal chemistry letters.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Adriano Lazzarin, Edwin DeJesus, Peter Sklar, 2009, The Lancet.

Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay.

D. Hazuda, M. Lai, Michael D Miller, 2008, Analytical biochemistry.

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

D. Cooper, M. Youle, R. Leavitt, 2010, The Lancet.

Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.

D. Nickle, L. van Doorn, D. Holder, 2019, The Journal of infectious diseases.

CHEMGENIE: integration of chemogenomics data for applications in chemical biology.

Anne Mai Wassermann, Meir Glick, Dante A. Pertusi, 2018, Drug discovery today.

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

M. Johnson, V. Miller, T. Peto, 2020, The Lancet.

A Randomized Comparison of Antiretroviral Therapy Alone Versus Antiretroviral Therapy with a 'Kick-and-Kill' Approach, on Measures of the HIV Reservoir Amongst Participants with Recent HIV Infection: The RIVER Trial

M. Johnson, M. Wills, A. Clarke, 2019, SSRN Electronic Journal.

A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals

D. Hazuda, D. Richman, F. Hecht, 2015, EBioMedicine.

Identification of proximal biomarkers of PKC agonism and evaluation of their role in HIV reactivation

D. Hazuda, A. Webber, D. Tellers, 2017, Antiviral research.

In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform

D. Hazuda, B. Howell, P. Zuck, 2021, SLAS discovery : advancing life sciences R & D.

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

A. Lazzarin, Jinrong Zhao, R. Leavitt, 2010, Journal of acquired immune deficiency syndromes.

Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a Novel In Vitro Pharmacodynamic System

D. Hazuda, G. Drusano, Ashley N Brown, 2011, Antimicrobial Agents and Chemotherapy.

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.

P. Kwo, W. Kraft, M. Sulkowski, 2013, Antiviral research.

Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat

D. Hazuda, A. Webber, D. Margolis, 2020, Journal of Virology.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

A. Lazzarin, R. Leavitt, R. Pollard, 2009, The Lancet.

Developing and applying ultrasensitive p24 protein immunoassay for HIV latency

D. Hazuda, M. Swanson, D. Graham, 2015 .

Approaches to Eradicate HIV Infection

D. Tellers, Richard J. O. Barnard, S. Wolkenberg, 2016 .